Biomaterial Database

[Clinical studies of bestatin on genitourinary cancer]. 1985

T Ichikawa, and I Hirokawa, and Y Ishihara

Bestatin was administered to 20 patients with urogenital tumors. The therapeutic results showed 12 surviving patients and 8 dead patients (including 7 due to cancer and 1 due to a cerebrovascular disorder). One patient has survived for 5 years since bestatin treatment of pulmonary metastasis of renal cancer, and one other patient achieved 5-year survival in spite of systemic metastases of testicular tumor. It is noteworthy that in earlier times these patients could have been expected to experience sudden relapse and aggravation, instead of the long-term survival recorded in this bestatin trial. Studies were conducted on the immunological parameters of the patients before and after the use of bestatin, and it was found that these parameters showed improvement as a result of the treatment. Even though bestatin was ingested for long periods of time by these patients, there was almost no development of adverse reactions to the treatment.

UI	MeSH Term	Description	Entries
D007680	Kidney Neoplasms	Tumors or cancers of the KIDNEY.	Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D007930	Leucine	An essential branched-chain amino acid important for hemoglobin formation.	L-Leucine,Leucine, L-Isomer,L-Isomer Leucine,Leucine, L Isomer
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D010412	Penile Neoplasms	Cancers or tumors of the PENIS or of its component tissues.	Cancer of Penis,Penile Cancer,Cancer of the Penis,Neoplasms, Penile,Neoplasms, Penis,Penis Cancer,Penis Neoplasms,Cancer, Penile,Cancer, Penis,Cancers, Penile,Cancers, Penis,Neoplasm, Penile,Neoplasm, Penis,Penile Cancers,Penile Neoplasm,Penis Cancers,Penis Neoplasm
D011471	Prostatic Neoplasms	Tumors or cancer of the PROSTATE.	Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D001749	Urinary Bladder Neoplasms	Tumors or cancer of the URINARY BLADDER.	Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000276	Adjuvants, Immunologic	Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.	Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants